Profitability
This table compares SQZ Biotechnologies and AlloVir’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
| AlloVir | N/A | -71.03% | -61.27% |
Earnings & Valuation
This table compares SQZ Biotechnologies and AlloVir”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SQZ Biotechnologies | $18.16 million | 0.04 | -$79.46 million | ($2.61) | -0.01 |
| AlloVir | N/A | N/A | -$190.42 million | ($20.23) | -0.22 |
Institutional & Insider Ownership
38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Summary
SQZ Biotechnologies beats AlloVir on 6 of the 10 factors compared between the two stocks.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About AlloVir
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
